Coherus Oncology, Inc.

CHRS Nasdaq CIK: 0001512762

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Accelerated filerSmaller reporting company
State of Incorporation DE
Business Address C/O DENNIS M. LANFEAR, REDWOOD CITY, CA, 94065
Mailing Address C/O DENNIS M. LANFEAR, REDWOOD CITY, CA, 94065
Phone (650) 649-3530
Fiscal Year End 1231
EIN 273615821

Financial Overview

FY2025

-$193.43M
Stockholders' Equity
$1.43
EPS

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G/A Passive ownership amendment March 26, 2026 View on SEC
8-K Current report of material events March 9, 2026 View on SEC
10-K Annual financial report March 9, 2026 View on SEC
8-K Current report of material events February 17, 2026 View on SEC
424B5 Prospectus supplement February 13, 2026 View on SEC
424B5 Prospectus supplement February 12, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 5, 2026 View on SEC
8-K Current report of material events February 4, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment January 30, 2026 View on SEC
4 Insider stock transaction report January 26, 2026 View on SEC

Annual Reports

10-K March 9, 2026
  • Coherus has strategically transformed into an oncology-focused biopharmaceutical company, divesting non-core assets.
  • The company generates revenue from key oncology products like Loqtorzi and manages typical biopharma expenses.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.